Bayer AG has announced the launch of Bayer Co.Lab AdVenture, a new platform designed to accelerate biotech innovation by connecting emerging startups with global venture capital networks. Introduced during the first anniversary of Bayer Co.Lab Shanghai, the platform aims to facilitate access to global financing, enabling the translation of early-stage ideas into impactful solutions. The initiative reflects Bayer's commitment to fostering innovation through collaboration, with inaugural partners including Shanghai Industrial Investment Capital, Legend Capital, IDG Capital, and Bayland Capital. Additionally, Bayer Co.Lab Shanghai welcomed new biotech startups OTR Therapeutics and Nutshell Therapeutics, whose research aligns with Bayer's strategic priorities in addressing high unmet medical needs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.
Comments